Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison

Ruggiero, Angelo; Fabbrocini, Gabriella; Cinelli, Eleonora; Megna, Matteo

doi:10.1016/j.jaad.2021.01.025

Cited by 36 publications

(36 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patients in the Italian study had undergone several biologic therapies before risankizumab, without success, which means that they represented difficult-to-treat cases, which could be the reason for a marginally higher reduction in mean PASI score in our study [11]. A similar reduction of PASI score in a real-life setting was described by Megna et al and also by Ruggiero et al, who indirectly compared risankizumab with guselkumab [15,16].…”

Section: Discussionsupporting

confidence: 53%

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Gkalpakiotis

Cetkovská

Arenberger

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Risankizumab has been approved for the treatment of moderate-to-severe plaque psoriasis; however, real-life data are limited. Our objectives were to evaluate the effectiveness and safety of risankizumab and its impact on the quality of life of patients with psoriasis in a realworld setting. Methods: We retrospectively analyzed 154 patients from 18 centers in the Czech Republic who had undergone biologic therapy with risankizumab for moderate-to-severe plaque psoriasis. Baseline characteristics included data on comorbidities, demographics, previous therapies, Dermatology Life Quality Index (DLQI) score, and Psoriasis Area and Severity Index (PASI) score. The proportion of patients achieving a 90% improvement in their PASI score from baseline (PASI 90) and complete resolution (PASI 100) after 16, 28, and 52 weeks was analyzed. Results: A total of 95 men and 59 women with mean body mass index (BMI) of 29.6 were enrolled in our analysis. The mean age of the patients was 48.5 years and the mean time from diagnosis until initiation of risankizumab therapy was 22.5 years. After 16 weeks, 63.8 and 44.7% patients achieved PASI 90 and PASI 100 responses, respectively. Improvement continued with time, and the proportion of patients with PASI 90 and PASI 100 responses increased to 82.4 and 67.6%, respectively, at week 52. A significant reduction was observed over time in the DLQI. Patients achieving PASI 100 response at week 16 had a higher reduction in the DLQI score than those with PASI 90 response (-15.9 vs. -11.8). PASI 90 and PASI 100 responses were independent of the BMI and previous biologic therapy. No new safety issues were identified. Conclusions: In this patient population, risankizumab was effective and safe in a real-world setting, and a high number of patients achieved PASI 90 and PASI 100 responses. A higher reduction in the DLQI was seen in patients withThe members of the BIOREP study group are listed in Acknowledgements.

show abstract

Section: Discussionsupporting

confidence: 53%

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Gkalpakiotis

Cetkovská

Arenberger

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…It revealed that 84% of patients treated with Guselkumab were able to achieve a PASI 90 at week 48, compared to 70% of patients treated with Secukinumab. In addition, a real life study has shown that Guselkumab may be a valid treatment option in psoriatic patients who failed therapy with Ustekinumab and Secukinumab 32,33 . Our center has experience in the use of both the aforementioned drugs, however limited to this study we can only note that 6/46 patients (13.04%) actually needed to switch from Secukinumab to Guselkumab.…”

Section: Discussionmentioning

confidence: 89%

A real‐life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis

Michelucci

Margiotta

Panduri

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Psoriasis is a skin disorder characterized by chronic inflammation driven by different immunologic pathways, among which the IL‐23/Th17 axis plays a pivotal role. For this reason, the use of IL23p19 inhibitors in psoriasis treatment has been evaluated over the years. Guselkumab, a totally human IgG1 lambda monoclonal antibody, that selectively blocks the p 19 subunit of IL‐ 23 has demonstrated high efficacy and safety throughout several, randomized, double‐blind phase III trials (VOYAGE 1 and 2, NAVIGATE and ECLIPSE). We designed a single‐center retrospective cohort study in a population consisting of 46 patients followed from December 2018 to April 2021. After a diagnosis of moderate to severe psoriasis, all the patients were considered suitable to receive treatment with Guselkumab. In our population, among those who achieved clinical improvement in terms of Psoriasis Area Severity Index (PASI), PASI 75, 90, and 100 were achieved on average on weeks 14, 19, 21 respectively. We then analyzed a subgroup of our population, consisting of 35 patients, who had an identical follow‐up time of 28 weeks, thus observing the trend in mean PASI at subsequent assessments and the number of patients who had reached PASI 75, PASI 90, and PASI 100 at week 4 (10; 3; 1), week 12 (12; 13; 11), week 20 (7; 6; 2), and week 28 (1; 4; 6), respectively. The results obtained are in line with those obtained from previous studies, thus confirming that Guselkumab is an excellent choice in terms of security, long‐term efficacy, and overall tolerance.

show abstract

“…In patients with moderate-to-severe plaque psoriasis, risankizumab demonstrated superior efficacy compared with placebo [ 18 , 19 ] and several systemic therapies in active-comparator studies, including fumaric acid esters [ 20 ], adalimumab [ 21 ], and ustekinumab [ 18 ]. While there are currently no head-to-head studies comparing IL-23–targeted agents, recent real-world evidence demonstrates favorable efficacy and safety in patients who received long-term IL-23 treatment during routine clinical practice [ 22 – 24 ]. Secukinumab is a fully human monoclonal antibody that inhibits IL-17A, and has shown greater skin clearance than ustekinumab, an inhibitor of IL-12 and IL-23 [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

Crowley¹,

Langley

Gordon

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Patients with moderate-to-severe plaque psoriasis who experience poor clinical outcomes, including patients with obesity or prior treatment, need improved treatment options. Risankizumab specifically inhibits interleukin 23 and has demonstrated superior efficacy in active-comparator studies in patients with moderate-to-severe plaque psoriasis. We compared the efficacy of risankizumab with that of secukinumab across patient subgroups.Methods: Subgroup analyses using data from the phase 3 IMMerge study (NCT03478787) were performed. Efficacy in adults with moderate-tosevere psoriasis treated with risankizumab 150 mg and secukinumab 300 mg was assessed as the proportion of patients who achieved C 90% improvement in Psoriasis Area Severity Index (PASI 90) at week 52 across demographics and disease characteristics. Post hoc analyses evaluated the proportion of patients who achieved PASI 90 and the least-squares mean percent PASI improvement from baseline at week 52 by body weight and body mass index (BMI), PASI 90 by prior treatment, and clinical response [PASI 90, PASI 100, and/or static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1)] at week 16 and maintained particular

show abstract

Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison

Cited by 36 publications

References 5 publications

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

A real‐life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

Contact Info

Product

Resources

About